Gliflozins Could Induce More Weight Loss Than GLP-1 Receptor Agonists in Diabetic Patients

Antidiabetic therapy with Gliflozins (SGLT2 inhibitors) causes more weight loss than therapy with GLP-1 receptor agonists, say researchers from the University of Buffalo. They reported the findings regarding this interesting study in the Journal of the American Pharmacists Association. Both Gliflozins and GLP-1 receptor agonists are used to treat type-2 diabetes if the use of metformin shows no effects. "Weight loss is an advantageous quality for diabetic medications as being overweight is a ...